Cargando…

Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?

Rituximab is an anti-CD-20 monoclonal antibody used in the management of lymphoproliferative disorders. The use of maintenance rituximab has improved progression free survival and overall survival in follicular lymphomas. Although rapid rituximab infusions have been studied extensively, there is lit...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Jolly, Ho, Melissa, Ho, Viet, Bello, Celeste, Djulbegovic, Benjamin, Sokol, Lubomir, Wetzstein, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833187/
https://www.ncbi.nlm.nih.gov/pubmed/24288618
http://dx.doi.org/10.1155/2013/629283
_version_ 1782291802485686272
author Patel, Jolly
Ho, Melissa
Ho, Viet
Bello, Celeste
Djulbegovic, Benjamin
Sokol, Lubomir
Wetzstein, Gene
author_facet Patel, Jolly
Ho, Melissa
Ho, Viet
Bello, Celeste
Djulbegovic, Benjamin
Sokol, Lubomir
Wetzstein, Gene
author_sort Patel, Jolly
collection PubMed
description Rituximab is an anti-CD-20 monoclonal antibody used in the management of lymphoproliferative disorders. The use of maintenance rituximab has improved progression free survival and overall survival in follicular lymphomas. Although rapid rituximab infusions have been studied extensively, there is little data on the use of rapid infusions during maintenance therapy for low grade lymphomas. The primary objective of this retrospective analysis was to evaluate the incidence of Grade 3 and 4 toxicities with maintenance rapid infusion rituximab according to the Common Terminology Criteria for Adverse Events version 4 (CTC v. 4). Secondary objectives included evaluating all grade infusion related adverse events and correlation of adverse events with varying schedules of rituximab maintenance therapy. All patients who received rapid infusion rituximab as maintenance therapy for low grade lymphoma between December 2007 and November 2011 were included. Rapid rituximab infusions were administered over 90 minutes. Demographic, laboratory and clinical data were collected. A total of 109 patients received 647 rapid rituximab infusions. Three patients experienced an adverse reaction which resulted in one grade 1 infusion reaction and three grade 3 infusion reactions. No patients required hospitalization. All 3 patients received pharmacological and/or supportive care to relieve symptoms associated with the reaction.
format Online
Article
Text
id pubmed-3833187
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38331872013-11-28 Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible? Patel, Jolly Ho, Melissa Ho, Viet Bello, Celeste Djulbegovic, Benjamin Sokol, Lubomir Wetzstein, Gene Leuk Res Treatment Clinical Study Rituximab is an anti-CD-20 monoclonal antibody used in the management of lymphoproliferative disorders. The use of maintenance rituximab has improved progression free survival and overall survival in follicular lymphomas. Although rapid rituximab infusions have been studied extensively, there is little data on the use of rapid infusions during maintenance therapy for low grade lymphomas. The primary objective of this retrospective analysis was to evaluate the incidence of Grade 3 and 4 toxicities with maintenance rapid infusion rituximab according to the Common Terminology Criteria for Adverse Events version 4 (CTC v. 4). Secondary objectives included evaluating all grade infusion related adverse events and correlation of adverse events with varying schedules of rituximab maintenance therapy. All patients who received rapid infusion rituximab as maintenance therapy for low grade lymphoma between December 2007 and November 2011 were included. Rapid rituximab infusions were administered over 90 minutes. Demographic, laboratory and clinical data were collected. A total of 109 patients received 647 rapid rituximab infusions. Three patients experienced an adverse reaction which resulted in one grade 1 infusion reaction and three grade 3 infusion reactions. No patients required hospitalization. All 3 patients received pharmacological and/or supportive care to relieve symptoms associated with the reaction. Hindawi Publishing Corporation 2013 2013-10-31 /pmc/articles/PMC3833187/ /pubmed/24288618 http://dx.doi.org/10.1155/2013/629283 Text en Copyright © 2013 Jolly Patel et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Patel, Jolly
Ho, Melissa
Ho, Viet
Bello, Celeste
Djulbegovic, Benjamin
Sokol, Lubomir
Wetzstein, Gene
Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
title Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
title_full Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
title_fullStr Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
title_full_unstemmed Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
title_short Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
title_sort rapid infusion rituximab for maintenance therapy: is it feasible?
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833187/
https://www.ncbi.nlm.nih.gov/pubmed/24288618
http://dx.doi.org/10.1155/2013/629283
work_keys_str_mv AT pateljolly rapidinfusionrituximabformaintenancetherapyisitfeasible
AT homelissa rapidinfusionrituximabformaintenancetherapyisitfeasible
AT hoviet rapidinfusionrituximabformaintenancetherapyisitfeasible
AT belloceleste rapidinfusionrituximabformaintenancetherapyisitfeasible
AT djulbegovicbenjamin rapidinfusionrituximabformaintenancetherapyisitfeasible
AT sokollubomir rapidinfusionrituximabformaintenancetherapyisitfeasible
AT wetzsteingene rapidinfusionrituximabformaintenancetherapyisitfeasible